A Controlled Clinical Study to Evaluate the Comparative Effect of Anuloma DS Tablet and Lactitol + Ispaghula Powder in Functional Constipation

The International Classification of Diseases (ICD) has described constipation as decrease in normal frequencyof defecation accompanied by difficult or incomplete passage of stool and/or passage of excessively hard, dry stool (ICD10-CM-K59). Overall, the average prevalence of constipation in adults has been estimated as 16% worldwide (varies between0.7% and 79%); in adults aged 60 to 110 years, the prevalence has been estimated to be 33.5%. Objective: To evaluate andcompare the efficacy of tablet Anuloma DS and lactitol + ispaghula powder in constipation. Materials and methods: Sixty‐twosubjects with constipation were divided into two groups: Group A with 32 subjects and Group B with 30 subjects. Group Areceived 1 Anuloma DS tablet at bedtime and Group B received lactitol + ispaghula powder 5 g at bedtime for 15 days.Results: Twenty-eight patients in Group A showed significant improvement in stool consistency, whereas just 8 patientsshowed improvement in consistency of stool in Group B. Twenty patients showed improvement in frequency of stool inGroup A, whereas only 3 patients showed this improvement in Group B. Twenty-nine patients in Group A reported goodimprovement in feeling after defecation compared to 9 patients in Group B. Pain in abdomen improved in 21 patients inGroup A versus 9 patients in Group B. Improvements were also seen in scores on the Constipation Assessment Scale, PatientAssessment Scale, and Quality of Life Questionnaire. Conclusion: Anuloma DS showed significant clinical benefits in thetreatment of constipation compared to lactitol + ispaghula powder.